SCHEMBL4313875

SCHEMBL4313875

COC(=O)c1ccc(C=Cc2n[nH]c3ccccc23)c(N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
STAT3 P40763 1/20 0.48
HIF1A Q16665 1/20 0.48
FLT3 P36888 2/20 0.47
KIF11 P52732 1/20 0.46
KDR P35968 11/20 0.43
CHEK1 O14757 2/20 0.43
FGFR1 P11362 2/20 0.43
BMPR1B O00238 1/20 0.43
PLK4 O00444 1/20 0.43
STK25 O00506 1/20 0.43
CIT O14578 1/20 0.43
RIOK3 O14730 1/20 0.43
IKBKB O14920 1/20 0.43
AURKA O14965 1/20 0.43
GAK O14976 1/20 0.43
DCLK1 O15075 1/20 0.43
CHUK O15111 1/20 0.43
MUSK O15146 1/20 0.43
EPHB6 O15197 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313873 1.00 KDM4E (0.48) KDM4ESTAT3HIF1AFLT3KIF11
SCHEMBL4309455 0.86 KDR (0.49) FLT3KDRCHEK1FGFR1BMPR1B
SCHEMBL4314034 0.86 KDR (0.49) FLT3KDRCHEK1FGFR1BMPR1B
SCHEMBL4314385 0.83 KDM4E (0.47) KDM4ESTAT3HIF1AFLT3KIF11
SCHEMBL4314384 0.83 KDM4E (0.47) KDM4ESTAT3HIF1AFLT3KIF11
SCHEMBL27626218 0.81 KDR (0.60) KDM4ESTAT3HIF1AFLT3KIF11
SCHEMBL1596140 0.81 KDR (0.60) KDM4ESTAT3HIF1AFLT3KIF11
SCHEMBL12381818 0.79 KDM4E (0.64) KDM4EALDH1A1GAAHPGDGLA
SCHEMBL4309530 0.77 JAK2 (0.56) FLT3KDRCHEK1FGFR1BMPR1B
SCHEMBL4309523 0.77 JAK2 (0.56) FLT3KDRCHEK1FGFR1BMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDM4E 1251/4885STAT3 437/4885HIF1A 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.